The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 28, 2025
Filed:
Apr. 30, 2021
The Regents of the University of California, Oakland, CA (US);
Cytomx Therapeutics, Inc., South San Francisco, CA (US);
Patrick Sean Daugherty, Santa Barbara, CA (US);
Nancy Stagliano, Santa Barbara, CA (US);
Jerry Thomas, Goleta, CA (US);
Kathryn Kamath, Santa Barbara, CA (US);
James W. West, Santa Barbara, CA (US);
Sanjay Khare, Newbury Park, CA (US);
Jason Sagert, Santa Barbara, CA (US);
The Regents of the University of California, Oakland, CA (US);
CytomX Therapeutics, Inc., South San Francisco, CA (US);
Abstract
The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an 'activatable' conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.